ELU535

ELU535 is a preclinical-stage small molecule therapeutic developed by Eluciderm, Inc. for the regeneration of elastic cartilage. Administered topically, the drug is part of Eluciderm's pipeline of compounds designed to activate the body's innate regenerative mechanisms. While specific target details for ELU535 are not explicitly disclosed in the provided pipeline, Eluciderm's platform generally focuses on the modulation of the Wnt signaling pathway to promote tissue repair and healing. ELU535 is specifically aimed at addressing conditions involving the loss or damage of elastic cartilage, a tissue type found in structures like the ears and epiglottis, which typically has limited self-repair capacity.